BRISTOL-MYERS SQUIBB COMPANY Inventory, Raw Materials and Supplies, Net of Reserves
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Inventory, Raw Materials and Supplies, Net of Reserves of $341.00 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Inventory › Inventory, Net, Items Net of Reserve Alternative
us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves · last filed 2026-07-30
- 2026-06-30: Inventory, Raw Materials and Supplies, Net of Reserves $341.00M.
- 2026-03-31: Inventory, Raw Materials and Supplies, Net of Reserves $310.00M.
- 2025-12-31: Inventory, Raw Materials and Supplies, Net of Reserves $281.00M.
- 2025-09-30: Inventory, Raw Materials and Supplies, Net of Reserves $312.00M.
| Period end | Inventory, Raw Materials and Supplies, Net of Reserves | Inventory, Raw Materials and Supplies, Net of Reserves as first filed |
|---|---|---|
| 2026-06-30 | $341.00M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $310.00M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $281.00M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $312.00M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $339.00M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $320.00M 10-Q · filed 2025-04-24 | |
| 2024-12-31 | $320.00M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $343.00M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $437.00M 10-Q · filed 2024-07-26 | |
| 2024-03-31 | $555.00M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $475.00M 10-K · filed 2025-02-12 | |
| 2023-09-30 | $461.00M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $451.00M 10-Q · filed 2023-07-27 | |
| 2023-03-31 | $594.00M 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $464.00M 10-K · filed 2024-02-13 | |
| 2022-09-30 | $446.00M 10-Q · filed 2022-10-26 | |
| 2022-06-30 | $422.00M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $446.00M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $350.00M 10-K · filed 2023-02-14 | |
| 2021-09-30 | $306.00M 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $270.00M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $219.00M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $207.00M 10-K · filed 2022-02-09 | |
| 2020-09-30 | $221.00M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $180.00M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $164.00M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $172.00M 10-K · filed 2021-02-10 | |
| 2019-09-30 | $127.00M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $217.00M 10-Q · filed 2019-07-25 | |
| 2019-03-31 | $214.00M 10-Q · filed 2019-04-25 | |
| 2018-12-31 | $116.00M 10-K · filed 2020-02-24 | $202.00M 10-K · filed 2019-02-25 |
| 2017-12-31 | $273.00M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |